Can bupropion (Buproprion) cause REM (Rapid Eye Movement) sleep disorder or movement disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bupropion can cause movement disorders, but the evidence provided does not specifically mention REM sleep movement disorders as a common side effect of bupropion. Bupropion, an antidepressant commonly sold under brand names like Wellbutrin and Zyban, works by inhibiting the reuptake of dopamine and norepinephrine in the brain. This mechanism can disrupt normal sleep architecture, but the provided evidence focuses more on its efficacy and safety in treating depression and smoking cessation rather than its effects on REM sleep.

Key Points to Consider

  • The most recent and highest quality study provided is from 2016 1, which discusses bupropion's use in smoking cessation and mentions its safety profile, including a reduced seizure threshold and potential neuropsychiatric effects, but does not specifically address REM sleep movement disorders.
  • Earlier studies, such as those from 2008 and 2009 1, provide information on bupropion's adverse effect profile, including insomnia and tremors, but again, do not specifically mention REM sleep movement disorders.
  • Given the lack of direct evidence from the provided studies linking bupropion to REM sleep movement disorders, it is essential to consult more recent and specific research on this topic for a definitive answer.

Clinical Considerations

  • If a patient experiences unusual movements during sleep while taking bupropion, it is crucial to discuss this with their healthcare provider.
  • The provider may consider reducing the dose, changing the timing of administration, switching to a different medication, or implementing sleep safety measures to prevent injury during episodes, based on the patient's overall clinical presentation and response to treatment.

From the FDA Drug Label

Tremor Twitch

The FDA drug label mentions tremor and twitch, which are related to movement disorders. However, it does not explicitly mention REM movement disorders.

  • Tremor is listed as an adverse reaction that occurred in at least 1% of patients treated with bupropion HCl sustained-release 300 mg/day and 400 mg/day.
  • Twitch is also listed as an adverse reaction that occurred in at least 1% of patients treated with bupropion HCl sustained-release 400 mg/day. Since the label does not directly address REM movement disorders, no conclusion can be drawn about bupropion causing this specific condition 2.

From the Research

Bupropion and REM Sleep Movement Disorders

  • Bupropion has been found to affect REM sleep in various studies, with some indicating an increase in REM sleep percent and REM time, as well as a reduction in REM latency 3.
  • However, the relationship between bupropion and REM sleep behavior disorder (RBD) is more complex, with some studies suggesting that antidepressants, including bupropion, may trigger symptoms of RBD in up to 6% of users 4.
  • RBD is a strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes, and it is unclear whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration 5, 4.
  • One study found that patients with antidepressant-associated RBD had a lower risk of developing neurodegenerative disease than those without antidepressant use, but still had markers of prodromal neurodegeneration present 4.

Effects of Bupropion on REM Sleep

  • Bupropion has been found to increase REM latency in responders to treatment, whereas non-responders showed a decrease in REM latency 6.
  • Another study found that bupropion SR treatment did not suppress electrophysiologic measures of REM sleep, nor did it alter an indirect measure of global metabolism during either waking or REM sleep 7.
  • However, bupropion SR treatment was found to reverse the deficit in anterior cingulate, medial prefrontal cortex, and right anterior insula activation from waking to REM sleep 7.

Clinical Implications

  • Patients with RBD should be treated with either melatonin or clonazepam to reduce injury potential 5.
  • Prospective outcome and treatment studies of RBD are necessary to enable accurate prognosis and better evidence for symptomatic therapy and future neuroprotective strategies 5, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.